New product approvals for New Zealand

4
th
August 2026

FOR PUBLIC RELEASE
Rua Bioscience New Zealand product approval
Tairawhiti, New Zealand – Rua Bioscience is pleased to report it has received approval
from the New Zealand Medicinal Cannabis Agency for five new medicinal cannabis
products.
The approval enables Rua to supply more products to patients in its home market of
Aotearoa. Rua expects sales in New Zealand to commence in the coming months, as
product becomes available.
Strategic importance
The approval supports Rua's domestic strategy. Establishing a New Zealand sales
pipeline is a first step toward the company's longer-term intention to incorporate its own
cannabis genetics, grown in Ruatōrea in Te Tairāwhiti, into products for the New Zealand
market.
Impact
The products will also support Tairawhiti based patients through Rua’s Compassionate
Access Programme which is designed to support patients facing financial constraints
when accessing medicine.

ENDS
The person who authorised this announcement:

Paul Naske
Chief Executive Officer
Paul.naske@ruabio.com
+64 21 445154